{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:43:51Z","timestamp":1789519431821,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373309"],"award-info":[{"award-number":["82373309"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.lungcan.2025.108457","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T11:52:17Z","timestamp":1740225137000},"page":"108457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study"],"prefix":"10.1016","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0423-3343","authenticated-orcid":false,"given":"Zhanming","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqiu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9081-0802","authenticated-orcid":false,"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lungcan.2025.108457_b0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108457_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1759-7714.12916","article-title":"Epidemiology of lung cancer in China","volume":"10","author":"Cao","year":"2019","journal-title":"Thorac Cancer."},{"key":"10.1016\/j.lungcan.2025.108457_b0015","doi-asserted-by":"crossref","unstructured":"Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. Dec 2015;10(12):1675-84. doi:10.1097\/JTO.0000000000000678.","DOI":"10.1097\/JTO.0000000000000678"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108457_b0020","doi-asserted-by":"crossref","first-page":"506","DOI":"10.21037\/tlcr.2020.03.40","article-title":"Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival","volume":"10","author":"Casal-Mourino","year":"2021","journal-title":"Transl Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108457_b0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","article-title":"Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial","volume":"178","author":"Lv","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108457_b0030","doi-asserted-by":"crossref","unstructured":"Group NM-aC. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. May 3 2014;383(9928):1561-71. doi:10.1016\/S0140-6736(13)62159-5.","DOI":"10.1016\/S0140-6736(13)62159-5"},{"key":"10.1016\/j.lungcan.2025.108457_b0035","doi-asserted-by":"crossref","unstructured":"Zhang Y, Fu F, Hu H, et al. Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study. J Thorac Cardiovasc Surg. Feb 2021;161(2):434-442 e2. doi:10.1016\/j.jtcvs.2020.02.131.","DOI":"10.1016\/j.jtcvs.2020.02.131"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108457_b0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108457_b0045","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108457_b0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108457_b0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108457_b0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijrobp.2015.02.005","article-title":"Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer","volume":"92","author":"Komaki","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108457_b0065","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108457_b0070","doi-asserted-by":"crossref","DOI":"10.1177\/0300060519887275","article-title":"Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients","volume":"48","author":"Xiong","year":"2020","journal-title":"J Int Med Res."},{"key":"10.1016\/j.lungcan.2025.108457_b0075","doi-asserted-by":"crossref","unstructured":"Xiong L, Li R, Sun J, et al. Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study. Oncologist. Feb 2019;24(2):157-e64. doi:10.1634\/theoncologist.2018-0120.","DOI":"10.1634\/theoncologist.2018-0120"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108457_b0080","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108457_b0085","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.lungcan.2025.108457_b0090","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study","volume":"37","author":"Zhong","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.lungcan.2025.108457_b0095","doi-asserted-by":"crossref","unstructured":"Piper-Vallillo A, Mak R, Lanuti M, et al. FP01.05 The ASCENT Trial: A Phase II Study of Neoadjuvant\/Adjuvant Afatinib, Chemoradiation +\/- Surgery for Stage III EGFR-Mutant NSCLC. J. Thorac. Oncol. 2021;16(3)doi:10.1016\/j.jtho.2021.01.072.","DOI":"10.1016\/j.jtho.2021.01.072"},{"issue":"31","key":"10.1016\/j.lungcan.2025.108457_b0100","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.2217\/fon-2021-0549","article-title":"Neoadjuvant osimertinib with\/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA","volume":"17","author":"Tsuboi","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2025.108457_b0105","doi-asserted-by":"crossref","unstructured":"Zhong WZ, Yan HH, Chen KN, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal Transduct Target Ther. Feb 24 2023;8(1):76. doi:10.1038\/s41392-022-01286-3.","DOI":"10.1038\/s41392-022-01286-3"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108457_b0110","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.20.01820","article-title":"Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial","volume":"39","author":"Zhong","year":"2021","journal-title":"J Clin Oncol."},{"issue":"23","key":"10.1016\/j.lungcan.2025.108457_b0115","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1158\/1078-0432.CCR-10-1588","article-title":"Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib","volume":"16","author":"Heon","year":"2010","journal-title":"Clin Cancer Res."},{"issue":"16","key":"10.1016\/j.lungcan.2025.108457_b0120","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1158\/1078-0432.CCR-12-0357","article-title":"The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations","volume":"18","author":"Heon","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108457_b0125","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/oncolo\/oyae107","article-title":"The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC","volume":"29","author":"Chang","year":"2024","journal-title":"Oncologist."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108457_b0130","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jtho.2018.11.020","article-title":"the unique spatial-temporal treatment failure patterns of adjuvant gefitinib therapy: a post hoc analysis of the ADJUVANT trial (CTONG 1104)","volume":"14","author":"Xu","year":"2019","journal-title":"J Thorac Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108457_b0135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/JTO.0000000000000053","article-title":"Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib","volume":"9","author":"Takeda","year":"2014","journal-title":"J Thorac Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108457_b0140","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/JTO.0b013e3182774108","article-title":"Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy","volume":"8","author":"William","year":"2013","journal-title":"J Thorac Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108457_b0145","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41379-021-00871-1","article-title":"Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer","volume":"34","author":"Liu","year":"2021","journal-title":"Mod Pathol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108457_b0150","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jtho.2018.11.017","article-title":"Pathologic assessment after neoadjuvant chemotherapy for NSCLC: importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma","volume":"14","author":"Qu","year":"2019","journal-title":"J Thorac Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225000789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225000789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T09:45:59Z","timestamp":1743846359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225000789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":30,"alternative-id":["S0169500225000789"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108457","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108457","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108457"}}